NMCV-5 vaccine: Vaccine effectiveness and assessment of the vaccine’s impact on meningococcal carriage in Niger

Thursday 20 August 2026 - Updated on Friday 28 August 2026
On-going
Period:
2024
-
2027

Study design

  • Matched case-control study 
  • A carriage study based on repeated cross-sectional surveys

Context

Caused by viral, bacterial, fungal and parasitic pathogens, meningitis epidemics in sub-Saharan Africa follow a seasonal and cyclical pattern, occurring mainly during the dry season and ending with the arrival of the rains. The majority of these epidemics are caused by Neisseria meningitidis (Nm), with up to 250,000 cases annually and a case-fatality rate of 10-15%. Historically, serogroup A was responsible for major epidemics, but its impact has been eliminated thanks to the introduction of the MenAfriVac® vaccine. However, five other Nm serogroups (B, C, Y, W, X) remain capable of causing epidemics, including outbreaks due to serogroups W and X, and more recently serogroup C in Niger and Nigeria. The Men5CV vaccine, designed to protect against the five major serogroups (A, C, Y, W, X), represents a promising solution, although its duration of protection remains unknown and data on its efficacy in real-life conditions are needed. 

 

Objective of the vaccine efficacy study 

  • To estimate the field effectiveness of NmCV-5 in reducing the risk of invasive meningococcal disease of serogroups A, C, W, Y and X in people vaccinated as part of a reactive vaccination campaign in response to an epidemic or a preventive vaccination campaign in high-risk districts.

     

Objective of the portage study

  • To measure changes in the portage prevalence of serogroups A, C, W, X and Y before and after the introduction of Men5CV, as well as their distribution. The study will also assess the direct effect amongst vaccinated individuals and the indirect effect amongst unvaccinated individuals.

Our role

Studies coordination 

Partners

  • World Health Organisation
  • Niger Ministry of Public Health 
  • Centers for Disease Control and Prevention USA

Results of the case-control study on vaccine effectiveness

Methodology

This is a matched case-control study in six health districts in Niger (Niamey I-V and Magaria) to assess the effectiveness of Men5CV against meningococcal meningitis. Cases were individuals aged 1-19 years with PCR confirmed disease, residing in vaccination areas, and presenting symptom onset at least 10 days after the campaign. Recruitment occurred between May 2024 and July 2025. Four community controls matched by age, sex, and residence were enrolled for each case. Vaccination status was verified by vaccination card when available or self-reported. Logistic regression models were used to estimate crude and adjusted vaccine effectiveness. 

Results 

A total of 17 confirmed cases (14 serogroup C and 3 serogroup W) and 68 matched controls were included. Vaccination was reported in 41% of cases and 86% of controls, although documentation was limited. Crude vaccine effectiveness was 88% (95% CI: 62-96) against all meningococcal meningitis and 86% (95% CI: 50-96) against serogroup C. After adjustment for household crowding and recent respiratory infections, effectiveness increased to 92% (95% CI: 72-98) overall and 91% (95% CI: 63-98) for serogroup C. 

Conclusion 

Men5CV demonstrated high effectiveness under real-world outbreak conditions overall. Limitations reliance on self-reported vaccination, and absence of cases from other serogroups. Further studies are needed to evaluate long-term protection, carriage impact, and effectiveness against invasive disease across all vaccine-targeted serogroups.

Video
Légende
Evaluation of the efficacy of the Nm5CV vaccine during the response campaign in Niger | Medard Djedanem

Read the publication

Effectiveness of NmCV-5 vaccine against meningococcal meningitis in an outbreak setting in Niger: results from a case-control study.

Journal Reference: Vaccine 2026 Aug 12; 90; . doi: 10.1016/j.vaccine.2026.128997. Epub 2026 08 12
See all

For more information, contact

Référence profils